Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT01252251 |
Title | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma |
Recruitment | Completed |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |